Johnson & Johnson (NYSE:JNJ) Shares Bought by Trust Point Inc.

Trust Point Inc. grew its stake in Johnson & Johnson (NYSE:JNJ) by 3.6% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 23,068 shares of the company’s stock after acquiring an additional 802 shares during the quarter. Trust Point Inc.’s holdings in Johnson & Johnson were worth $3,336,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of JNJ. AMF Tjanstepension AB lifted its stake in shares of Johnson & Johnson by 14.2% in the 3rd quarter. AMF Tjanstepension AB now owns 425,261 shares of the company’s stock valued at $68,985,000 after purchasing an additional 52,997 shares during the last quarter. Alpha Financial Partners LLC purchased a new stake in Johnson & Johnson in the 3rd quarter valued at about $209,000. Brookstone Capital Management boosted its stake in Johnson & Johnson by 5.5% during the third quarter. Brookstone Capital Management now owns 73,811 shares of the company’s stock worth $11,962,000 after buying an additional 3,842 shares during the period. Strategic Wealth Partners Ltd. increased its position in shares of Johnson & Johnson by 2.0% during the third quarter. Strategic Wealth Partners Ltd. now owns 6,401 shares of the company’s stock valued at $1,037,000 after acquiring an additional 128 shares during the last quarter. Finally, Brightwater Advisory LLC raised its stake in shares of Johnson & Johnson by 3.4% in the 3rd quarter. Brightwater Advisory LLC now owns 3,713 shares of the company’s stock valued at $602,000 after acquiring an additional 122 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity

In other news, Director Mark A. Weinberger acquired 1,000 shares of Johnson & Johnson stock in a transaction on Thursday, December 12th. The stock was bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. Citigroup dropped their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Guggenheim boosted their price objective on Johnson & Johnson from $162.00 to $166.00 and gave the company a “neutral” rating in a report on Monday. Raymond James lowered their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Argus upgraded shares of Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Finally, Morgan Stanley lowered their price objective on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $170.67.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $153.46 on Friday. The stock’s 50-day simple moving average is $147.49 and its 200-day simple moving average is $156.08. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The firm has a market capitalization of $369.47 billion, a PE ratio of 23.08, a price-to-earnings-growth ratio of 2.44 and a beta of 0.52. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The company’s revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.29 EPS. As a group, equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.23%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.